Neumora Therapeutics, Inc. (NASDAQ:NMRA) — Market Cap & Net Worth
Market Cap & Net Worth: Neumora Therapeutics, Inc. (NMRA)
Neumora Therapeutics, Inc. (NASDAQ:NMRA) has a market capitalization of $127.45 Million ($127.45 Million) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #18367 globally and #4293 in its home market, demonstrating a -37.50% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Neumora Therapeutics, Inc.'s stock price $0.75 by its total outstanding shares 169938441 (169.94 Million). Also see Neumora Therapeutics, Inc. total assets for a full breakdown of the balance sheet.
Neumora Therapeutics, Inc. Market Cap History: 2023 to 2026
Neumora Therapeutics, Inc.'s market capitalization history from 2023 to 2026. Data shows change from $2.90 Billion to $127.45 Million (-64.53% CAGR). Also see cash efficiency ratio of Neumora Therapeutics, Inc. for how efficiently the company converts equity into cash flow.
Index Memberships
Neumora Therapeutics, Inc. is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.67 Trillion | 0.00% | #515 of 976 |
|
NASDAQ Composite
IXIC
|
$41.95 Trillion | 0.00% | #1789 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.88 Trillion | 0.01% | #239 of 263 |
Weight: Neumora Therapeutics, Inc.'s market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Neumora Therapeutics, Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Neumora Therapeutics, Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Neumora Therapeutics, Inc. stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of NMRA by Market Capitalization
Companies near Neumora Therapeutics, Inc. in the global market cap rankings as of September 18, 2026. Review NMRA tangible net assets ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Neumora Therapeutics, Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #185 globally with a market cap of $130.87 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #337 globally with a market cap of $79.84 Billion USD.
- CSL Ltd (AU:CSL): Ranked #455 globally with a market cap of $60.95 Billion USD ( AU$86.14 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #504 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #185 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.87 Billion | $516.34 |
| #337 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.84 Billion | $789.45 |
| #455 | CSL Ltd | AU:CSL | $60.95 Billion | AU$177.56 |
| #504 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $158.07 |
Neumora Therapeutics, Inc. Historical Marketcap From 2023 to 2026
Between 2023 and today, Neumora Therapeutics, Inc.'s market cap moved from $2.90 Billion to $ 127.45 Million, with a yearly change of -64.53%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $127.45 Million | -58.10% |
| 2025 | $304.19 Million | -83.11% |
| 2024 | $1.80 Billion | -37.83% |
| 2023 | $2.90 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 18th, 2026 the market cap of Neumora Therapeutics, Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $127.45 Million USD |
| MoneyControl | $127.45 Million USD |
| MarketWatch | $127.45 Million USD |
| marketcap.company | $127.45 Million USD |
| Reuters | $127.45 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Neumora Therapeutics, Inc.
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive diso… Read more